

DOCKET NO.: PHOE-0061 PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Charles Mark Ensor, et al.

Application No.: 09/921,380

Filing Date: August 2, 2001

For: PEG-MODIFIED URICASE

Confirmation No.: 7237

Group Art Unit: 1652

Examiner: Patterson, Charles L Jr.

EXPRESS MAIL LABEL NO: EV 325644340 US.

DATE OF DEPOSIT: June 15, 2004

EV325644340US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is
being filed either within three months of the filing date of the above-identified
application, within three months of the date of entry into the national stage of
the above identified application as set forth in § 1.491, before the mailing date
of a first Office Action on the merits of the above-identified application, or

	before the mailing d	ate of a first Office Action after the filing of request for				
	continued examination	on under § 1.114, no additional fee is required.				
	In accordance with {	§ 1.129(a), this Information Disclosure Statement is being				
	filed in connection	with the first or second After Final Submission,				
	therefore:					
	Certif	ication in Accordance with § 1.97(e) is attached; or				
	The fe	ee of <u>\$180.00</u> as set forth in § 1.17(p) is attached.				
	In accordance with	§ 1.97(c), this Information Disclosure Statement is being				
	filed after the period set forth in § 1.97(b) above but before the mailing date of					
	either a Final Action	under § 1.113 or a Notice of Allowance under § 1.311, or				
	before an action that	otherwise closes prosecution in the application, therefore:				
		Certification in Accordance with § 1.97(e) is attached;				
		or ·				
		The fee of $$180.00$ as set forth in § 1.17(p) is attached.				
\boxtimes	In accordance with	§ 1.97(d), this Information Disclosure Statement is being				
	filed after the mailin	g date of either a Final Action under § 1.113 or a Notice				
	of Allowance under	§ 1.311 but before, or simultaneously with, the payment				
	of the Issue Fee, the	erefore included are: Certification in Accordance with §				
	1.97(e); and the subr	nission fee of \$180.00 as set forth in § 1.17(p).				

\boxtimes	Copie	Copies of each of the references listed on the attached Form PTO-1449 are						
	enclos	sed herewith.						
	Copie	s of references listed on the attached Form PTO-1449 are enclosed						
	herew	ith						
	Copie	s of references listed on the attached Form PTO 1449 are not required to						
	be sul	omitted pursuant to the June 30, 2003 recent revisions to 37 CFR §						
	1.98(a)(2)(i).						
	EXCE	PT THAT:						
		In view of the voluminous nature of references [list as appropriate],						
		and the likelihood that these references are available to the Examiner,						
		copies are not enclosed herewith.						
		In accordance with § 1.98(d), copies of the following references listed						
		on the attached Form PTO-1449 are not enclosed herewith because						
		they were previously cited by or submitted to the U.S. Patent and						
		Trademark Office in patent application(s) for which a claim for priority						
		under 35 U.S.C.§ 120 have been made in the instant application:						
		Copies of references [list as appropriate] listed on the						
		attached Form PTO-1449 were previously cited by or submitted						
		to the Patent and Trademark Office in prior Application No.						
		filed .						

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: June 15, 2004

Patrick J. Farley, Ph.D. Registration No. 42,524

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor

Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2004 WW



DOCKET NO.: PHOE-0061 PATENT

AUG 0 4 2004 PARADEMARKS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Charles Mark Ensor, et al.

Application No.: 09/921,380

Filing Date: August 2, 2001

For: PEG-MODIFIED URICASE

Confirmation No.: 7237

Group Art Unit: 1652

Examiner: Patterson, Charles L., Jr.

EXPRESS MAIL LABEL NO: EV 325644340 US

DATE OF DEPOSIT: June 15, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

ln	accordance	with 37	CFR §	-1.97(e), certification	is heret	y mac	ie t	tha	t:
----	------------	---------	-------	---------	------------------	----------	-------	------	-----	----

Each item of information contained in the information disclosure statement
was first cited in any communication from a foreign patent office in a
counterpart foreign application not more than three months prior to the filing
of the Information Disclosure Statement.

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Date: June 15, 2004

Patrick J. Farley, Ph.D. Registration No. 42,524

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2004 WW



COPY

BEST AVAILABLE COPY

RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE

Paper: Supplemental Information Disclosure Statement (in duplicate); w/Express Mailing Label No:. EV 325644340 US;USPTO-1449 (1 page(s)); 2 reference(s) cited/ 2 reference(s) submitted, Certification Under 37 C.F.R, Check in the amount of \$180.00, return postcard

Applicant(s): Charles Mark Ensor, et al.

Title: PEG-MODIFIED URICASE

Serial No: 09/921,380 **Filed:** August 2, 2001

Docket No:. PHOE-0061

Date Sent: June 15, 2004 Sent By: PJF/D.M. De Santo



AUG 0 4 2004

EXAMINER

Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket No. PHOE-0061	Application No. 09/921,380	
Applicant Charles Mark E	Ensor, et al.	

Filing Date Group
August 2, 2001 1652

Confirmation No. 7237

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	40	6,576,235 B1	06/10/03	Williams, et al.	424	94.4
	41	2003/0166249 A1	09/04/03	Williams, et al.	435	227
-			ļ	,		
						· ·
	<u> </u>	FORE	EIGN PATI	ENT DOCUMENTS		
Examiner					Tra	nslation
Initial	<u> </u>	Document No.	Date	Country	YES	NO
					,	

DATE CONSIDERED

© 2004 WW